By writer to www.globenewswire.com
SAN FRANCISCO, Might 05, 2020 (GLOBE NEWSWIRE) — Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical firm targeted on the invention, growth, and commercialization of novel small molecule therapeutics to deal with acute organ accidents and fibrotic ailments, at the moment introduced the publication of a peer-reviewed article within the scientific journal Transplantation presenting outcomes from its Section 2 medical trial of ANG-3777 in transplant-associated acute kidney harm. The publication, authored by Jonathan S. Bromberg, M.D., Ph.D., et al., is titled, “Renal Operate Enchancment Following ANG-3777 Therapy in Sufferers at Excessive Danger for Delayed Graft Operate after Kidney Transplantation.”
“We consider the publication of the Section 2 knowledge in Transplantation additional validates ANG-3777 as a possible therapy for acute organ accidents akin to transplant-associated acute kidney harm, also called delayed graft operate, a extreme and probably life-threatening situation with out efficient therapeutic choices,” stated Dr. Jay Venkatesan, Angion’s President and Chief Government Officer. “Our enthusiasm round this program is supported by these Section 2 outcomes exhibiting ANG-3777 was typically well-tolerated and led to clinically significant enhancements as in comparison with placebo in a number of key endpoints, together with eGFR. We stay up for additional validating the therapeutic promise of ANG-3777 and reporting knowledge from our ongoing Section three registration trial of ANG-3777.”
This publication particulars the outcomes of the administration of ANG-3777 in sufferers who’ve undergone deceased-donor kidney transplantation and had indicators of kidney harm, putting them at excessive threat for delayed graft operate. This Section 2 medical trial was a multi-center, randomized, double blind, placebo-controlled medical trial. Topics have been sufferers receiving renal transplantation producing lower than 50 cc of urine per hour for eight consecutive hours over the primary 24 hours following transplantation, and/or demonstrating a creatinine discount ratio <30% from pre-transplantation to 24 hours post-transplantation. Sufferers have been randomized 2:1 to obtain three once-daily intravenous infusions of ANG-3777 or placebo. The first endpoint was variety of days to producing > 1,200 cc of urine over 24 hours.
Jonathan Bromberg, M.D., Ph.D., Professor of Surgical procedure and Microbiology and Immunology and Vice Chair for Analysis at College of Maryland and lead writer of the publication added, “Our findings present additional help ANG-3777 has the potential to symbolize a big enchancment over present customary of take care of sufferers in want of an efficient therapeutic possibility.”
The total publication could be accessed at: https://doi.org/10.1097/tp.0000000000003255
About Delayed Graft Operate
Delayed graft operate (DGF) is a extreme type of acute kidney harm ensuing from ischemia-reperfusion harm following kidney transplantation. It’s distinct from transplant rejection and is mostly seen in recipients of deceased-donor kidneys, partly because of the longer durations of heat ischemia (ischemia occurring at physique temperature) and chilly ischemia (ischemia occurring throughout kidney preservation and transport) typical for deceased-donor kidney transplants. DGF is mostly outlined as the necessity for dialysis (the extracorporeal elimination of waste merchandise from the blood when the kidneys are in a state of failure) inside seven days following transplantation. Sufferers who expertise DGF have a discount in transplant survival. There are at the moment no accredited therapies to stop or scale back the severity of DGF.
ANG-3777, is a small molecule designed to imitate the organic exercise of hepatocyte development issue (HGF), thereby activating the c-Met cascade of pathways concerned in tissue restore and organ restoration. ANG-3777 has demonstrated a number of similarities to HGF, together with c-Met dependence and selective c-Met receptor activation, with out performing on different development issue receptors. As well as, it has a considerably longer half-life than HGF. Because of this, we consider ANG-3777 has the potential to be a first-in-class therapeutic with a novel method to addressing acute organ harm as a result of it has the power to reinforce key pure organ restore pathways, develop the therapy window after acute organ harm, and has had a positive opposed occasion profile based mostly upon knowledge from early medical trials. Enrollment is ongoing in a placebo-controlled Section three registration trial inspecting the efficacy of ANG-3777 in DGF and in a Section 2 medical trial for the therapy of acute kidney harm related to cardiac surgical procedure involving cardiopulmonary bypass.
About Angion Biomedica Corp.
Angion Biomedica Corp. is a late-stage biopharmaceutical firm targeted on the invention, growth, and commercialization of novel small molecule therapeutics to deal with acute organ accidents and fibrotic ailments. Angion’s lead product candidate, ANG-3777, is a small molecule designed to imitate the organic exercise of hepatocyte development issue (HGF) to activate the HGF/c-Met pathway, which has a central position in tissue restore and organ restoration. Enrollment is ongoing in a placebo-controlled Section three registration trial inspecting the efficacy of ANG-3777 in lowering the severity of transplant-associated acute kidney harm, also called delayed graft operate, in sufferers in danger for kidney dysfunction. ANG-3777 can also be in a Section 2 medical trial for the therapy of acute kidney harm related to cardiac surgical procedure involving cardiopulmonary bypass. Angion can also be creating ANG-3070, an orally-bioavailable small molecule, as a possible therapy for fibrotic ailments utilizing a precision-medicine method. For additional info, please go to www.angion.com.
Cherilyn Cecchini, M.D.
LifeSci Public Communications